FEXUPRAZAN HCL

✨ ‌Fexuprazan Hydrochloride (CAS 1902954-87-3) | High-Purity Potassium-Competitive Acid Blocker (P-CAB)‌ ✨

🧪 ‌Product Overview‌

‌Fexuprazan Hydrochloride‌ (CAS 1902954-87-3), also known as ‌Abeprazan HCl‌, is a potent ‌potassium-competitive acid blocker‌ (P-CAB) with the molecular formula ‌C₁₉H₁₈ClF₃N₂O₃S‌ and a molecular weight of ‌446.87‌. This white to light-yellow crystalline powder (purity ≥98%) is designed for ‌acid-related gastrointestinal disorder treatment‌, offering rapid and sustained suppression of gastric acid secretion. It acts by inhibiting H+/K+-ATPase in gastric parietal cells, making it a superior alternative to traditional proton pump inhibitors (PPIs) with faster onset and longer duration.

‌Key Functions‌:

• Treats gastroesophageal reflux disease (GERD) and peptic ulcers.

• Enhances Helicobacter pylori eradication therapy efficacy.

• Serves as a pharmaceutical intermediate for advanced formulations.

‌Target Industries‌: Pharmaceutical manufacturing, clinical research, and biotechnology.

⭐ ‌Key Advantages‌

🏭 ‌Applications‌

• ‌GERD Management‌: Oral tablets or capsules for chronic acid reflux relief.

• ‌Peptic Ulcer Therapy‌: Combined with antibiotics for H. pylori eradication.

• ‌Drug Development‌: Intermediate for novel P-CAB formulations and bioavailability studies.

📊 ‌Quality Assurance‌

• ‌Testing Standards‌: Complies with ‌USP/EP‌ pharmacopeial guidelines.

• ‌Analytical Validation‌: HPLC, NMR, and LC-MS for identity and impurity profiling.

• ‌Certifications‌: ISO 9001 and GMP compliance for pharmaceutical-grade production.

📈 ‌Market Insights‌

The global GERD treatment market is projected to reach ‌$6.8 billion by 2030‌, driven by rising prevalence of acid-related disorders and demand for non-PPI therapies. Fexuprazan is gaining traction in ‌Asia-Pacific‌ due to cost-effective manufacturing and expanding healthcare infrastructure.